Results 181 to 190 of about 10,365,683 (253)

Choroidal Assessment in Patients with Type 2 Diabetes Mellitus and Non-Proliferative Diabetic Retinopathy by Swept-Source Ocular Coherence Tomography and Image Binarization. [PDF]

Medicina (Kaunas), 2022
Obadă O, Pantalon AD, Rusu-Zota G, Hăisan A, Lupuşoru SI, Chiseliţă D.   +5 more
europepmc   +1 more source

Effects of age, sex, and renal function on bowel movement‐improving effects of Bifidobacterium bifidum G9‐1 on constipation in patients with type 2 diabetes mellitus and chronic kidney disease: A prespecified subgroup analysis of the BIRDIE study

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1759-1769, October 2026.
This prespecified subgroup analysis of the BIRDIE study demonstrated that Bifidobacterium bifidum G9‐1 improved stool consistency, bowel movement, and quality of life in patients with type 2 diabetes mellitus, chronic kidney disease, and specifically in age ≥ 65 years, male, and those with eGFR ≥60 mL/min/1.73 m2.
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Hiroaki Satoh, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +8 more
wiley   +1 more source

Multifocal intraocular lenses improve near vision but increase optical aberrations in patients with non-proliferative diabetic retinopathy. [PDF]

Am J Transl Res
Liu X, Yang P, Gao X, Wang J.
europepmc   +1 more source

Epidemiology of moderately severe and severe non-proliferative diabetic retinopathy in South West England. [PDF]

Eye (Lond), 2022
Nevill CR, Stratton IM, Maruti SS, Massó-González EL, Sivaprasad S, Bailey C, Ehrlich M, Chong V, Scanlon PH.   +8 more
europepmc   +1 more source

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1726-1734, October 2026.
We conducted the single‐center, retrospective cohort study to evaluate and compare the risk of diabetic eye and kidney complications between newly initiated once‐daily liraglutide (0.9 mg) and once‐weekly dulaglutide (0.75 mg) in 331 Japanese patients with type 2 diabetes.
Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami   +4 more
wiley   +1 more source

Downregulation of MerTK in circulating T cells of patients with non-proliferative diabetic retinopathy. [PDF]

Front Endocrinol (Lausanne)
Bu S, Ling JY, Wu X, Zhang L, Shi X, Huang L, Zhao Z, Yang Y, Xiang Z, Liu YU, Liu Y, Zhang Y.   +11 more
europepmc   +1 more source

Comparison of VEGF level in tears post phacoemulsification between non-proliferative diabetic retinopathy and non-diabetic patients. [PDF]

J Diabetes Metab Disord, 2021
Azhan A, Zunaina E, Mahaneem M, Siti-Azrin AH.   +3 more
europepmc   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Effect of Chinese herbal compounds on ocular fundus signs and vision in conventional treated-persons with non-proliferative diabetic retinopathy: A systematic review and meta-analysis. [PDF]

Front Endocrinol (Lausanne), 2022
Li X, Zhang J, He R, Su X, Li Z, Xie X.
europepmc   +1 more source

Dyslipidemia and reduced retinal layer thicknesses in mild to moderate non-proliferative diabetic retinopathy. [PDF]

Am J Transl Res
Wu J, Chen Y, Huang C, Wang Y, Lin L, Zhang Z.   +5 more
europepmc   +1 more source